VOR BIOPHARMA INC. - COMMON STOCK

Vor Bio Appoints Life Sciences and Technology Investor and Entrepreneur, Mr. Erez Kalir to its Board of Directors

08 1月 2025 09:00:00 条件 Nasdaq GlobeNewswire

Vor Bio Announces $55.6 Million Private Placement

27 12月 2024 09:00:15 条件 Nasdaq GlobeNewswire

Vor Bio Provides Clinical Update Further Validating Approach of Using Shielded Transplants to Deliver Targeted Therapies; Receives Supportive Feedback from FDA Regarding Registrational Trial Design

09 12月 2024 07:30:00 条件 Nasdaq GlobeNewswire

Vor Bio to Participate in the Stifel 2024 Healthcare Conference

12 11月 2024 08:00:02 条件 Nasdaq GlobeNewswire

Vor Bio Reports Third Quarter 2024 Financial Results and Provides Company Update

07 11月 2024 16:05:01 条件 Nasdaq GlobeNewswire

Vor Bio Appoints Seasoned Healthcare Institutional Investor, Han Choi, M.D., LL.M., as Chief Financial Officer

30 9月 2024 07:00:00 条件 Nasdaq GlobeNewswire

New Clinical Data Validates Vor Bio’s Approach of Using Shielded Transplants to Deliver Targeted Therapies

05 9月 2024 16:01:00 条件 Nasdaq GlobeNewswire

Vor Bio to Participate in Upcoming Investor Conferences

28 8月 2024 08:00:00 条件 Nasdaq GlobeNewswire

Vor Bio Reports Second Quarter 2024 Financial Results and Provides Company Update

08 8月 2024 16:05:02 条件 Nasdaq GlobeNewswire

Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

02 8月 2024 16:01:00 条件 Nasdaq GlobeNewswire

Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

09 7月 2024 16:01:00 条件 Nasdaq GlobeNewswire

Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

04 6月 2024 16:01:00 条件 Nasdaq GlobeNewswire

Vor Bio Reports First Quarter 2024 Financial Results and Provides Company Update

09 5月 2024 16:05:00 条件 Nasdaq GlobeNewswire

Vor Bio to Participate in Upcoming Investor Conferences

06 5月 2024 08:00:00 条件 Nasdaq GlobeNewswire

Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

03 5月 2024 16:01:00 条件 Nasdaq GlobeNewswire

Vor Bio Appoints Accomplished Oncology and Cancer Immunotherapy R&D Executive, Fouad Namouni, M.D., to its Board of Directors

02 5月 2024 16:01:00 条件 Nasdaq GlobeNewswire

Vor Bio to Participate in Upcoming Investor Conferences

01 4月 2024 08:00:00 条件 Nasdaq GlobeNewswire

Vor Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Company Update

20 3月 2024 16:05:00 条件 Nasdaq GlobeNewswire

Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

05 3月 2024 16:01:00 条件 Nasdaq GlobeNewswire

Vor Bio to Participate in Upcoming Investor Conferences

04 3月 2024 08:00:00 条件 Nasdaq GlobeNewswire